A Phase 2/3 observer-blind, randomized, controlled study to determine the safety and immunogenicity of SARS-CoV-2 recombinant spike protein vaccine in Indian children and adolescents aged 2 to 17 years

Bhagwat Gunale, MD[a], Dhananjay Kapse, MD[a], Sonali Kar, MD[b], Ashish Bavdekar, DNB[c], Sunil Kohli, MD[d], Sanjay Lalwani, MD[e], Sushant Meshram, MD[f], Abhishek Raut, MD[g], Praveen Kulkarni, MD[h], Clarence Samuel, MD[i], Renuka Munshi, DNB[j], Madhu Gupta, MD[k], Joyce Plested, PhD[l], Shane Cloney-Clarke, BS[l], MingZhu Zhu, PhD[l], Melinda Pryor, PhD[m], *Stephanie Hamilton PhD[m]*, Madhuri Thakar M.Sc. PhD[n], Ashwini Shete, MD[n], Abhijeet Dharmadhikari, M.Sc.[a], Chetanraj Bhamare, MD[a], Umesh Shaligram, PhD[a], Cyrus S. Poonawalla, DSc[a], Raburn M. Mallory, MD[l], Gregory M Glenn, MD[l], Prasad S. Kulkarni MD[a], for the COVOVAX-Ped Study Group*

[a]Serum Institute of India Pvt Ltd., Pune India, [b]Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India, [c]KEM Hospital Research Centre, Pune, Maharashtra, India, [d]Hamdard Institute of Medical Sciences and Research with Centre for health Research and Development (CHRD), New Delhi, India, [e]Bharati Vidyapeeth Deemed University Medical College and Hospital, Pune, Maharashtra, India, [f]Super Speciality Hospital, Government Medical College and Hospital, Nagpur, Maharashtra, India, [g]Sushila Nayar School of Public Health, Mahatma Gandhi Institute of Medical Sciences, Wardha, Maharashtra, India, [h]JSS Academy of Higher Education and Research, Mysore, Karnataka, India, [i]Christian Medical College & Hospital, Ludhiana, Punjab, India, [j]TN Medical College & BYL Nair Hospital, Mumbai, Maharashtra, India, [k]Post Graduate Institute of Medical Education and Research, Chandigarh, India, [l]Novavax, Inc. 21 Firstfield Road, Gaithersburg, MD 20878, USA, [m]360biolabs Pty Ltd, Melbourne, 3004, Victoria, Australia, [n]Indian Council of Medical Research, National AIDS Research Institute, Pune, India,

Author for correspondence:
Prasad S. Kulkarni,
Serum Institute of India Pvt. Ltd.,
Poonawalla Biotechnology Park SEZ,
Manjari (Bk), Taluka: Haveli, Dist: Pune PIN 412307, India

Tele: +91 20 71946820 / 71946000 Email ID: drpsk@seruminstitute.com

Abstract:

Background:

A recombinant, adjuvanted COVID-19 vaccine, SII-NVX-CoV2373 was manufactured in India and evaluated in Indian children and adolescents to assess safety and immunogenicity.

Methods:

This was a Phase 2/3 observer-blind, randomized, controlled study in children and adolescents aged 2 to 17 years. Participants were randomly assigned in 3:1 ratio to receive two doses of SII-NVX-CoV2373 or placebo on day 1 and day 22. Solicited adverse events (AEs) were collected for 7 days after each vaccination. Unsolicited AEs were collected for 35 days following first dose and serious AEs (SAEs) and adverse events of special interest (AESI) were collected throughout the study. Anti S IgG and neutralizing antibodies against the SARS-CoV-2 were measured at baseline, day 22, day 36 and day 180. Variant immune responses were assessed in a subset of participants at baseline, day 36 and day 180. Primary objectives were to demonstrate non-inferiority of SII-NVX-CoV2373 in each pediatric age group (12 to 17 years and 2 to 11 years, separately) to that in adults in terms of ratio of titers of both anti-S IgG and neutralizing antibodies 14 days after the second dose (day 36). Non-inferiority was to be concluded if the lower bound of 95% CI of the ratio was >0.67.

Results:

A total of 920 children and adolescents (460 in each age cohort; 12 to 17 years and 2 to 11 years) were randomized and vaccinated. The demographic and baseline characteristics between the two groups were comparable in both age groups. After the second dose, there were more than 100-fold rise in anti-S IgG GMEUs and more than 84-fold rise in neutralizing antibodies GMTs from baseline in the participants who received SII-NVX-CoV2373. The GMTs in both age groups were non-inferior to those observed in Indian adults. The seroconversion rate was ≥ 98% (anti-S IgG) and ≥ 97.9 % (neutralizing antibodies) in both age groups, respectively. Similar findings were seen in the baseline seronegative participants. SII-NVX-CoV2373 also

showed robust responses against various variants of concern. Injection site pain, tenderness, swelling, erythema and fever, headache, malaise, fatigue, myalgia, arthralgia, nausea and vomiting were the common solicited adverse events which were transient and resolved without any sequelae. Throughout the study, only two causally unrelated SAEs and no AESI were reported.

Conclusion:

SII-NVX-CoV2373 has been found safe and well tolerated in children and adolescents of 2 to 17 years. The vaccine was highly immunogenic and the immune response was non-inferior to that in adults.

Key Words: SII- NVX-CoV2373, vaccine, immunogenicity, safety, children

Registration - CTRI No. CTRI/2021/02/031554

Research in context

Evidence before this study

We searched PubMed for research articles published from 01 January 2020 (before the start of the pandemic) until 06 December 2022, with no language restrictions, using the terms "SII-NVX-CoV2373", "vaccine", "SARS-CoV-2 recombinant spike protein nanoparticle vaccine", "clinical trial", "children of 2 to 17 years", "children", and "adolescents" no publications were found on SII-NVX-CoV2373 in the pediatric population of 2 to 17 years. There was one publication on NVX-CoV2373 as a pre-print in adolescents (12-17 years) from a study conducted in the United States.

Added value of this study

This is the first worldwide report on the safety and immunogenicity of SII-NVX-CoV2373 vaccine in Indian children and adolescents of 2 to 17 years of age. The vaccine was found safe and well tolerated. SII-NVX-CoV2373 in Indian children (2 to 11 years) and adolescents (12 to 17 years) demonstrated non-inferior immune response in terms of anti-S IgG and neutralizing antibodies to Indian adults who had received SII-NVX-CoV2373. In addition, SII-NVX-CoV2373 also demonstrated immune responses in terms of anti-S IgG antibodies and hACE2 inhibition activity against Delta, Omicron BA.1, Omicron BA.5 variants.

Implications of all the available evidence

NVX-CoV2373 was found safe and efficacious in adolescents in USA. SII-NVX-CoV2373 in pediatric population was found non-inferior to SII-NVX-CoV2373 in Indian adults and also demonstrated immune response against variants of concern. This data provides evidence that SII-NVX-CoV2373 will provide protection against COVID-19 in children 2 to 17 years, including those caused by emerging variants of concern. Though the pandemic seems to have receded, it

is possible that the young children and new birth cohorts may remain susceptible and therefore, there could be a need for vaccinating these cohorts. The excellent results from the present study can be helpful to the policy makers and the scientific community.

Introduction

In the Covid-19 pandemic, adults were at high risk of severe disease and deaths. While children are generally considered as a lower risk population [1-3], there have been cases of severe COVID-19 and also deaths reported in children. Many of these children had some underlying medical conditions [4-6]. Moreover, children are also known to be carriers of the virus and can spread the virus among the adults [7].

Considering all of these issues, pediatric vaccination has been considered very important. National Health Service, United Kingdom, US Centers for Disease Control and prevention and many other medical bodies recommend vaccination of the pediatric population [8-10]. Two mRNA vaccines have been approved or authorized in the USA for the age group of 6 months to 17 years [11]. In India, an inactivated vaccine and a receptor binding domain (RBD) based vaccines have also been approved for pediatric population from the age of 5 years and above [12].

NVX-CoV2373, a SARS-CoV-2 recombinant spike protein nanoparticle vaccine was originally developed by Novavax in the USA. The vaccine has been found safe and has also shown high efficacy of 90% in adults [13,14]. After a technology transfer, the vaccine is also manufactured in India by Serum Institute of India Pvt. Ltd. (SIIPL). This vaccine (SII-NVX-COV2373) has been tested in Indian adults and was found safe and immunogenic with more than 92% seroconversion with different antibody assays[15]. The vaccine has been granted emergency use authorization (EUA) in India and has received emergency use listing (EUL) by the World Health Organization [16,17]. SII-NVX-CoV2373 was subsequently evaluated in the pediatric population. The present paper summarizes the results of this study.

Materials and Methods

The study was approved by the Indian regulatory authorities and Institutional Ethics Committees. The ICH Good Clinical Practice guidelines and the Declaration of Helsinki were

followed. All children were enrolled after written informed consent of their parents, which was also audio visually recorded. In addition, a verbal assent from 7 to 11 years old children and a written assent for 12 to 17 years old children were also obtained.

The primary objective of this study was to assess non-inferiority of SII-NVX-CoV2373 in adolescents of 12 to 17 years age and children of 2 to 11 years separately against that in the adult participants of the same study.[15] Non-inferiority was to be demonstrated in terms of ratio of geometric mean of ELISA units of anti-spike IgG antibodies as well as GMTs of neutralizing antibodies against SARS-CoV-2 at 14 days after the second dose. Another primary objective was to assess the safety of the study vaccine in comparison to placebo in terms of solicited local and systemic adverse events, unsolicited adverse events, serious adverse events and adverse events of special interest.

This is a Phase 2/3 observer-blind, randomized, controlled study in children and adolescents of 2 to 17 years of age in India. A total of 920 eligible children and adolescents were enrolled in this study, 460 in the 12 to 17 years age group and 460 in the 2 to 11 years age group. The participants were randomly assigned in 3:1 ratio to receive 2 doses of either SII-NVX-CoV2373 or placebo on day 1 and day 22. After vaccination, participants visited study sites on day 22 and day 36, day 85 and day 180. All participants were contacted telephonically on day 120 for safety follow up.

The recruitment happened in a stepwise manner. 100 participants were first enrolled in the 12 to 17 years age group. After review of the day 8 safety data by the Independent Data Safety Monitoring Board (DSMB) and the Indian regulatory authorities, the rest of the participants of this age group and 100 participants of the 7 to 11 years age group were enrolled. After the day 8 safety data of the first 100 participants from 7 to 11 years age group was reviewed by the DSMB and Indian regulatory authorities, the rest of the participants of this age group and 100 participants of the 2 to 6 years age group were enrolled. After day 8 safety data review by the DSMB and Indian regulatory authorities, remaining participants of the 2 to 6 years age group were enrolled.

Safety was monitored during the study by onsite clinical staff. Safety data was reviewed at periodic intervals by the protocol safety review team (PSRT), an internal group of physicians, biostatisticians and a pharmacovigilance medical officer. In addition, an independent DSMB reviewed the safety data and provided an oversight on the study.

In all participants, approximately 6 ml blood was collected at baseline, day 22,day 36 and day 180 for immunogenicity testing. A nasopharyngeal swab was collected for detection of SARS-CoV-2 infection at baseline. Solicited, local and systemic adverse events through 7 days after each dose were collected using diary cards. The parents were provided with digital thermometer, measuring scale and a diary.

Study Population

Participants were healthy or medically stable children of ≥ 2 through 17 years of age. Female participants of 12 to 17 years of age who had attained menarche were required to have a negative urine pregnancy test at study entry. Children with any acute illness, history of COVID-19 disease, prior receipt of COVID-19 vaccine, severe allergic reactions, immunocompromised condition, were excluded from the study.

Study Products

The study vaccines were administered intramuscularly in the deltoid or anterolateral aspect of thigh as two doses of 0.5 ml each on day 1 and day 22 (+7 days). Covovax (SII-NVX-CoV2373 manufactured by SIIPL) is available as ready to use liquid formulation in a 10-dose vial. Each single dose of 0.5 ml contains 5 μg antigen and 50 μg Matrix-M™ adjuvant(Batch No. 4301Z001, Manufacturing date July 2021, manufactured by SIIPL). A solution of 0.9% sodium chloride (NaCl) was used as a placebo (Batch No. 0700I002, Manufacturing date Jan2020, manufactured by SIIPL).

Safety assessment

The solicited adverse events were collected for 7 days after each vaccination. The solicited local AEs included pain, tenderness, erythema, swelling and induration. The solicited systemic AEs included fever, headache, fatigue, malaise, arthralgia, myalgia, nausea and vomiting. Unsolicited adverse events were collected for 14 days after second dose. SAEs, related medically attended AEs (MAAEs) and AESI were collected throughout the 180 days of study participation. AESIs included potential immune-mediated conditions (PIMMCs), adverse events specific to COVID-19 or other potential adverse events that may have been determined at any time by regulatory authorities (Refer Protocol in Supplementary Appendix).

At any time during the study, if any participant presented with symptoms of suspected COVID-19 or had a history of contact with a confirmed COVID-19 case, the participant was tested by RT-PCR for SARS-CoV-2.

Immunogenicity Assessment

Immunogenicity was assessed by Anti-Spike (anti-S) IgG antibodies and neutralizing antibodies against SARS-CoV-2 to prototype strain on days 1, 22, 36 and 180. Anti-S IgG antibodies were measured by validated ELISA assay (Novavax Clinical Immunology, Gaithersburg, USA). Neutralizing antibodies against SARS-CoV-2 were measured using a validated virus neutralizing assay (VNA) with wild type virus (SARS-CoV-2 hCoV-19/Australia/ VIC01/2020, GenBank MT007544.1) (360Biolabs, Melbourne, Australia). Anti-N (nucleocapsid) IgG antibodies were measured at baseline by Chemiluminescence Microparticle immune assay (NARI-Indian Council of Medical Research, Pune, India) using ARCHITECT SARS-CoV-2 IgG kit (6R86) (Abbott).
Immunogenicity against Delta, Omicron BA.1 and Omicron BA.5 variants were also assessed in a subset of participants by IgG antibodies by ELISA assay on days 1, 36 and 180. In addition, immune response against ancestral strain (Wuhan), Delta, Omicron BA.1 and Omicron BA.5 variants were determined in a subset by human ACE2 receptor inhibition assay on days 1, 36 and 180. Both assays were conducted at Novavax Clinical Immunology, Gaithersburg, USA.

Statistical Analysis

The study had 82% power to detect at least one serious adverse event among 690 children and adolescents administered SII-NVX-CoV2373, if the frequency of causally related SAEs was 1 in 400. In each of the pediatric cohort age group (2 to 11 years and 12 to 17 years), 345 participants received the SII-NVX-CoV2373 vaccine and 115 received placebo. The proportion of non-evaluable participants was assumed to be ≤ 20%, which led to sample size 276 evaluable participants. The study had over 99% statistical power to achieve a non-inferiority objective in terms of GMEU ratio compared with 276 adult participants who had received SII-NVX-CoV2373. Non-inferiority was to be concluded if the lower limit of the two-sided 95% CI for the GMEU ratio for Anti-S IgG antibodies and GMT ratio of neutralizing antibodies for SII-NVX-CoV2373 between each pediatric age group (2 to 11 years) and (12 to 17 years) and adult cohort was more than 0.67, as per the WHO guidelines for clinical evaluation of vaccines.[18] Additional assumptions were one sided significance level of 0.025, a zero difference in the antibody titers between pediatric and adult participants (i.e. a GMEU / GMT ratio of 1 and coefficient variation of 1.35. Sample size calculations were performed using a non-inferiority test for the ratio of two means in PASS 15.0.7 Version software.

All participants who received at least one dose of study vaccine were part of the safety population. The Immunogenicity population consisted of all participants who received the first dose of the study vaccine and provided an evaluable serum sample for at least one assessment and had baseline data available. The immunogenicity population excluded any data from time points following of SARS-CoV-2 infection or from participants with major protocol deviations impacting the study outcomes.

For the primary immunogenicity analysis, ANCOVA fitted to the log transformed anti-S IgG as well as neutralizing antibodies with terms for vaccine group, log baseline titer and sex to compare each pediatric cohort versus adult cohort participants vaccinated with SII-NVX-CoV2373 for primary endpoint.

Categorical data are expressed as proportions while quantitative data are expressed as mean and SD.

All statistical analyses were performed using SAS® Software version 9.4 or later.

RESULTS

This analysis includes data collected for the entire study i.e. until the day 180 visit of all participants from ≥ 12 to < 18 (12 to 17) years of age and ≥ 2 to < 12 (2 to 11) years of age.

Disposition of Participants:

A total of 470 participants 12 to 17 years of age were enrolled (screened) and 461 were randomized. Among these 461 participants, 460 received the first dose of study vaccine (346 SII-NVX-CoV2373 and 114 Placebo) and 445 received the second dose of study vaccine (335 SII-NVX-CoV2373 and 110 Placebo). Fifteen participants withdrew the consent before the second dose. The safety population comprised all 460 participants and immunogenicity analysis population comprised 441 participants (Figure 1). The demographic and baseline characteristics between the two groups were comparable [Table 1].

A total of 474 participants 2 to 11 years of age were enrolled (screened) and 460 were randomized and received the first dose of study vaccine (345 SII-NVX-CoV2373 and 115 Placebo) and 445 received the second dose of study vaccine (333 SII-NVX-CoV2373 and 112 Placebo). Fifteen participants withdrew before the second dose. The safety population comprised all 460 participants and immunogenicity analysis population comprised 437 participants (Figure 2). The demographic and baseline characteristics between the two groups were comparable [Table 1].

Immunogenicity Results:

Anti-S IgG against ancestral strain (Wuhan)

Baseline GMEUs of anti-S IgG to prototype strain were comparable between the SII-NVX-CoV2373 and the Placebo groups in both 12-17 years and 2-11 years age group. After the second dose, there was 101.9 fold-rise (12-17 years) and 169.2 fold-rise (2-11 years) in the anti-S IgG in the SII-NVX-CoV2373 group. There was negligible rise in the placebo groups. On day 180, there was a decline in titres, but still they were 37-fold higher (12-17 years) and 31-fold higher (2-11 years) than the baseline in the SII-NVX-CoV2373 group. The corresponding values

in the placebo group were 8.1 fold (12-17 years) and 3.4-fold (2-11 years) [Table 3]. The fold-rises in the baseline negative participants (negative for both anti-N IgG and RT-PCR for SARS CoV-2), were more than 123-fold in both the age groups. On day 180, they were still more than 38-fold higher than the baseline in the SII-NVX-CoV2373 group in both the age groups. The corresponding values in the placebo group was more than 4-fold in both the age groups [Table S1].

Non-inferiority for SII-NVX-CoV2373 for each pediatric cohort separately (12-17 years and 2-11 years) in comparison to the adult cohort was met using anti-S IgG titers, with 1.08 as the lower bound of 95% CI in the 12 to 17 years age group and with 1.38 as the lower bound of 95% CI in the 2-11 year age group [Table 2].

On day 36, there was 98.8% seroconversion (12-17 years) and 99.1% (2-11 years) after the second dose in the SII-NVX-CoV2373 group and it was less than 7.8% in the Placebo group. On day 180, the seroconversion was still more than 90% in both the age groups who received SII-NVX-CoV2373. In the placebo group, this increased to 43% and 73% in 2-11 year and 12-17 year age groups, respectively [Table 4]. In the baseline seronegative participants on day 36, this was 99.3% (12-17 years) and 100% (2-11 years) in the SII-NVX-CoV2373 group while it was less than 8.7% in the Placebo group. In this population too, the seroconversion rate was still more than 90% in both the age groups on day 180. In the placebo group, this increased to 43% and 73% in 2-11 year and 12-17-year age groups, respectively [Table S2].

Neutralizing antibodies (nAbs) against ancestral strain (Wuhan)

Baseline GMTs of neutralizing antibodies (nAbs) were comparable between the SII-NVX-CoV2373 and the Placebo group in both the age groups. After the second dose, there was 84.9 fold-rise (12-17 years) and 115.3 fold-rise (2-11 years) in nAbs GMTs from the baseline in the SII-NVX-CoV2373 group. On day 180, there was still 45.3-fold-rise (12-17 years) and 29-fold-rise (2-11 years) in the SII-NVX-CoV2373 group [Table 3]. In the baseline seronegative participants, the corresponding values were more than 98-fold (12-17 years) and 138-fold (2-11 years) on day 36 and more than 54-fold (12-17 years) and 34-fold (2-11 years) on day 180. There was no rise in the Placebo group on day 36, whereas 7.4-fold rise (12-17 years) and 2.9-fold rise (2-11 years) from the baseline was seen on day 180 [Table S1].

Non-inferiority for each pediatric cohort in comparison to the adult cohort was met, with 1.17 and 1.70 as the lower bound of 95% CI of GMT ratio in 12-17 years and 2-11 years age groups, respectively [Table 2].

On day 36, there was more than 98% seroconversion after the second dose in the SII-NVX-CoV2373 group in both age groups while it was more than 91% on day 180. [Table 4]. It was more than 98% and more than 94% in baseline negative participants in both age groups, on days 36 and 180, respectively. In the same population, there was less than 12% seroconversion in the placebo group on day 36 and 76.5% in 12- 17 years and 41.7% in 2-11 years age groups on day 180 [Table S2].

Immunogenicity against variants

Compared to baseline, there was around 70- to 100-fold rise and 17- to 40-fold rise in anti-S IgG antibodies against Delta, Omicron BA.1 and Omicron BA.5 variants on day 36 and day 180, respectively in the SII-NVX-CoV2373group [Table S3].

In terms of hACE2 receptor binding inhibition GMTs, there was around 20- to 40-fold rise and 9-fold rise against Delta, Omicron BA.1 and Omicron BA.5 variants on day 36 and day 180, respectively in the SII-NVX-CoV2373 group. For the Wuhan strain, the rise was 67- and 13.2-fold on day 36 and day 180, respectively [Table S4].

Safety Results

SAEs and AESIs:

Among 12-17 year adolescents, two SAEs were reported in vaccine recipients which were viral infection and gastroenteritis. Both these events were assessed as causally unrelated to the study vaccine. No AESI was reported in the study. Among 2 to 11 year old children, there were no SAEs or AESIs reported.

Unsolicited AEs: In the 12 to 17 year age group, a total of 30 AEs were reported in 28 participants (8.1%) in the SII-NVX-CoV2373 group and 12 AEs in 6 participants (5.3%) in the Placebo group. None of these were considered causally related to the study vaccines except for the event of diarrhea in the Placebo group.

In the 2 to 11 year age group, a total of 49 AEs were reported in 39 participants (11.3%) in the SII-NVX-CoV2373 group and 14 AEs in 13 participants (11.3%) in the Placebo group. None of these were considered causally related to the study vaccines except for the three events (1 each of pyrexia, allergic dermatitis, and diarrhea) in the SII-NVX-CoV2373 group and one in the placebo group (diarrhea).

Almost all AEs were of mild severity and all resolved without any sequelae.

Solicited AEs: In the 12 to 17 year age group, after the first dose, there were 271 solicited AEs reported in 138 participants (39.9%) in the SII-NVX-CoV2373 group whereas 54 solicited AEs were reported in 26 participants (22.8%) in the placebo group. After the second dose, there were 322 solicited AEs reported in 126 participants (37.6%) in the SII-NVX-CoV2373 group whereas 41 solicited AEs were reported in 19 participants (17.3%) in the placebo group. The common AEs in both the groups included injection site pain, tenderness, headache, fatigue, fever [Table 5].

In the 2 to 11 year age group, there were 248 solicited AEs reported in 122 participants (35.4%) in the SII-NVX-CoV2373 group whereas 29 solicited AEs were reported in 15 participants (13.0%) in the Placebo group after the first dose. There were 367 solicited AEs reported in 163 participants (48.9%) in the SII-NVX-CoV2373 group whereas 27 solicited AEs were reported in 13 participants (11.6%) in the Placebo group after the second dose. In this age group as well, the common AEs in both the groups included injection site pain, tenderness, headache, fatigue, fever [Table 5].

Almost all AEs were of mild severity and all resolved without any sequalae. Most of the solicited AEs started within 1 day and lasted for 1 to 2 days in both the age groups.

Discussion

The present study evaluated safety and immunogenicity of SII-NVX-CoV2373 in Indian children and adolescents of 2-17 years. The vaccine was highly immunogenic with more than 98% seroconversion for both anti-S IgG and neutralizing antibodies in adolescents of 12 to 17 years of age and children of 2 to 11 years of age. There was a more than 84-fold rise from baseline for both anti-S IgG and neutralizing antibodies. No AESI was reported and no causally related SAE

was reported. SII-NVX-CoV2373 is safe and well tolerated in the pediatric population of 2-17 years of age.

An age effect was clearly seen in the immune responses. Not only did both 12 to 17 years adolescents and 2 to 11 years children age groups show non-inferior immune responses to adults, but in fact, the titers in both the pediatric age groups were higher than in adults [15]. Moreover, the titers in the 2 to 11 years age group were also higher than in the 12 to 17 years age group. It is known that the younger populations mount higher immune response as compared to older population [19].

To our knowledge this is the first study in India in which any recombinant protein COVID-19 vaccine has been tested between 2 to 5 years of age. mRNA vaccines have been tested and recommended for use in 6 month to 5 years population [20]. In general, there has been a concern of myocarditis with mRNA vaccines in younger populations [21-24]. So far SII-NVX-CoV2373 has not been found to cause any related SAE or AESI in this study as well as in previous studies conducted in India, though the size of the study populations has been small.

The day 180 results showed decline in IgG as well as neutralizing antibodies in the vaccine group, though they were still much higher than the baseline titres and much higher than the placebo group. There was a small rise in the titres in the placebo groups compared to baseline likely due to SARS-CoV-2 infections. In terms of seroconversion, there was a small decline though it was still more than 90%. These results are on expected lines as seen with SII-NVX-CoV2373 in adults [15].

The GMTs and seroconversion in placebo groups on day 180 were significantly higher as compared to baseline. This was probably due to the Omicron wave that affected all age groups in the country during December 2021-March 2022. Even there, the titres were higher in the 12-17 years age group as compared to 2-11 years. Again, this could be due to higher infections in older children as compared to younger children. As of 24 July 2022, children of 5-14 years and

those less than 5 years of age had 10.44% and 2.47% infections during Omicron wave, respectively [25].

We also tested a subset of participants for immune response against variants of concern. SII-NVX-CoV2373 showed high GMTs as well as seroconversions for Delta, BA.1 and BA.5 variants though slightly lower than those for the Wuhan strain. This is known with other vaccines [25]. Still such high titres indicate that vaccines based on the Wuhan strain are likely to give protection from various variants, especially for severe disease and deaths.

Pediatric COVID-19 vaccination has faced some degree of hesitancy among parents [27-29]. One study in Canada found that despite parents' high COVID-19 vaccination uptake for themselves (88.8%), intentions for vaccinating children aged 5–11 years was low (56%) [30]. As a result, the vaccine coverage has not been optimum [31]. Some important reasons for the low coverage have been concerns about vaccine safety and effectiveness [32]. There is also a perception that the risk for serious COVID-19–associated illness is low in children [32]. On this background, the safety profile in children can be an advantage of the SII-NVX-CoV2373.

Baseline serology and/or RT-PCR positivity for SARS-CoV-2 was around 10-13% in both the pediatric age groups. The corresponding value in the Phase 3 study in adults was around 33% [15]. The recruitment of adults in Phase 3 study happened during March 2021 to July 2021, of 12 to 17 years started in Aug 2021 to Nov 2021; whereas of 2 to 11 years was between Sep 2021 to Feb 2022. This probably means that the first wave in 2020 as well as the second wave in 2021 and third wave in 2021-2022 in India did not affect children significantly. However, another study conducted during March-June 2021 showed a seroprevalence of 55.7% in the <18 years age group and 63.5% in the ≥18 years age group in India [33]. While this study measured total antibodies against S-RBD SARS-CoV-2 virus, our study measured anti-N IgG antibodies. Disparities in prevalence estimate obtained using different serological assays are known [34].

NVX-CoV2373 has shown around 90% efficacy in adults [13,14]. The immune responses by SII-NVX-CoV2373 in children were much higher than that seen in adults [15]. Higher levels of all

immune markers are known to correlate with a reduced risk of symptomatic infection [35]. Human challenge studies of seasonal coronaviruses reported high levels of baseline neutralizing antibodies in uninfected or asymptomatic people [36]. Considering these factors, SII-NVX-CoV2373 is expected to give high degree of protection in children.

Our study had a few potential limitations. We excluded previous known SARS-CoV-2 infection cases from the study. However, because of this, we could assess the actual vaccine effect and no response was seen in the placebo group until 14 days after the second dose. We did not assess efficacy of the vaccine in our study population. However, NVX-CoV2373 has already demonstrated efficacy in two large studies [13,14] and therefore, SII-NVX-Cov2373 with identical composition as NVX-Cov2373 could be bridged immunologically.

To conclude, SII-NVX-COV2373 was safe and well tolerated in children of 2 to 17 years age group; the vaccine was highly immunogenic and showed higher immune response than in adults and also showed robust responses against various variants of concern. The vaccine may be used in the pediatric vaccination drive against COVID-19.

Acknowledgements :

We gratefully acknowledge the contribution by our DSMB members Drs. Sharad Agarkhedkar, Charudatta Joglekar and Ommen John. We acknowledge the study participants and their parents. We also acknowledge PPD for contribution to study monitoring, data management and statistical analysis for the study.

Funding :

The study was funded by Serum Institute of India Pvt. Ltd.

Conflict of Interest:

CSP is Chairman and Managing Director of SIIPL. PSK, BG, DK and US are employed by Serum Institute of India Pvt. Ltd., which is the manufacturer of the study vaccine. JSP, MZ, SCC, RM, FD, GMG are employees of Novavax Inc. MP and SH are employees of 360biolabs All other authors declare no competing interests.

References:

1. Steinman JB, Lum FM, Ho PP, Kaminski N, Steinman L. Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics. Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):24620-24626.

2. Davies NG, Klepac P, Liu Y, Prem K, Jit M; CMMID COVID-19 working group, Eggo RM. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020 Aug;26(8):1205-1211.

3. Molteni E, Sudre CH, Canas LS, et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health. 2021 Oct;5(10):708-718.

4. Docherty AB, Harrison EM, Green CA, et al. Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020 May 22;369:m1985.

5. hopal SS, Bagaria J, Olabi B, Bhopal R. Children and young people remain at low risk of COVID-19 mortality. Lancet Child Adolesc Health. 2021 May;5(5):e12-e13.

6. Smith C, Odd D, Harwood R, et al. Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat Med. 2022 Jan;28(1):185-192.

7. Paul LA, Daneman N, Schwartz KL, et al. Association of Age and Pediatric Household Transmission of SARS-CoV-2 Infection. JAMA Pediatr. 2021;175(11):1151–1158.

8. Coronavirus (COVID-19) vaccine for children aged 5 to 15. https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-covid-19-vaccination-for-children/coronavirus-covid-19-vaccine-for-children-aged-5-to-15/ Accessed on 12 August 2022.

9. COVID-19 Vaccines for Children and Teens. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html Accessed on 12 August 2022.

10. Vaccines for children: COVID-19. https://www.canada.ca/en/public-health/services/vaccination-children/covid-19.html Accessed on 12 August 2022.

11. Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children Accessed on 12 August 2022.

12. NTAGI panel recommends use of Covid vaccines Corbevax, Covaxin for kids aged 5-12 years. https://indianexpress.com/article/india/ntagi-panel-recommends-use-of-covid-vaccines-corbevax-covaxin-for-kids-aged-5-12-years-8017862/ Accessed on 12 August 2022.

13. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021 Sep 23;385(13):1172-1183.

14. Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med. 2022 Feb 10;386(6):531-543.

15. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4153455. Accessed on 06 Aug 2022

16. Panel recommends EUA for COVID-19 vaccines Covovax, Corbevax and anti-Covid pill Molnupiravir. https://www.thehindu.com/news/national/cdsco-panel-recommends-restricted-emergency-use-of-anti-covid-pill-molnupiravir/article38051321.ece Accessed on 12 August 2022.

17. WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries. https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries#:~:text=lower%2Dincome%20countries-,WHO%20lists%209th%20COVID%2D19%20vaccine%20for%20emergency%20use%20with,vaccination%20in%20lower%2Dincome%20countries&text=Today%2C%20the%20World%20Health%20Organization,SARS%2DCoV%2D2%20virus. Accessed on 12 August 2022.

18. World Health Organization (WHO). Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO Technical Report Series 1004, Annex 9, 2017. October 21, 2020. https://www.who.int/publications/m/item/WHO-TRS-1004-webannex-9. Date accessed 03 Dec 2022.

19. Lord JM. The effect of ageing of the immune system on vaccination responses. Hum Vaccin Immunother. 2013 Jun;9(6):1364-7.

20. https://www.cdc.gov/media/releases/2022/s0618-children-vaccine.html. Date accessed 28 Nov 2022

21. Shimabukuro T. COVID-19 vaccine safety updates: Vaccines and Related Biological Products Advisory Committee (VRBPAC).US Food and Drug Administration. Published June 10, 2021. Accessed July 4, 2021. https://www.fda.gov/media/150054/download

22. Truong DT, Dionne A, Muniz JC, et al. Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination. Circulation. 2022 Feb;145(5):345-356.

23. Luk A, Clarke B, Dahdah N, et al. Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. Can J Cardiol. 2021 Oct;37(10):1629-1634.

24. Massari M, Spila Alegiani S, Morciano C, et al. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study. PLoS Med. 2022 Jul 28;19(7):e1004056.

25. WHO Dashboard COVID-19 cases and deaths [Available from: https://app.powerbi.com/view?r=eyJrIjoiYWRiZWVkNWUtNmM0Ni00MDAwLTljYWMtN2EwNTM3YjQzYmRmIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9. Dated accessed 28 Nov 2022

26. Price AM, Olson SM, Newhams MM, et al. BNT162b2 Protection against the Omicron Variant in Children and Adolescents. N Engl J Med. 2022 May 19;386(20):1899-1909.

27. Alfieri NL, Kusma JD, Heard-Garris N, Davis MM, Golbeck E, Barrera L, Macy ML. Parental COVID-19 vaccine hesitancy for children: vulnerability in an urban hotspot. BMC Public Health. 2021 Sep 13;21(1):1662.

28. Gray A, Fisher CB. Determinants of COVID-19 Vaccine Uptake in Adolescents 12-17 Years Old: Examining Pediatric Vaccine Hesitancy Among Racially Diverse Parents in the United States. Front Public Health. 2022 Mar 22;10:844310.

29. Fisher CB, Gray A, Sheck I. COVID-19 Pediatric Vaccine Hesitancy among Racially Diverse Parents in the United States. Vaccines (Basel). 2021 Dec 27;10(1):31.

30. Humble RM, Sell H, Wilson S, et al. Parents' perceptions on COVID-19 vaccination as the new routine for their children ≤ 11 years old. Prev Med. 2022 Aug;161:107125.

31. DeCuir J, Meng L, Pan Y, et al. COVID-19 Vaccine Provider Availability and Vaccination Coverage Among Children Aged 5-11 Years - United States, November 1, 2021-April 25, 2022. MMWR Morb Mortal Wkly Rep. 2022 Jul 1;71(26):847-851.

32. Liu Y, Ma Q, Liu H, Guo Z. Public attitudes and influencing factors toward COVID-19 vaccination for adolescents/children: a scoping review. Public Health 2022;205:169–81.

33. Misra P; Kant S; Guleria R; et al. Serological prevalence of SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in India: An interim result from a large multicentric population-based seroepidemiological study. Journal of Family Medicine and Primary Care: June 2022 - Volume 11 - Issue 6 - p 2816-2823

34. Coelho LE, Luz PM, Pires DC, et al. Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey. Lancet Reg Health Am. 2022 Nov;15:100338.

35. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021 Nov;27(11):2032-2040.

36. Callow KA. Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection. J Hyg (Lond). 1985 Aug;95(1):173-89.

Table 1: Demographics and Baseline Characteristics – (Safety Population)

Parameter	2-11 years		12-17 years	
	SII-NVX-CoV2373 (N=345)	Placebo (N=115)	SII-NVX-CoV2373 (N=346)	Placebo (N=114)
Age (Years), Mean (SD)	6.7 (2.66)	6.5 (2.70)	14.3 (1.55)	14.3 (1.64)
Sex, n (%)				
Male	176 (51.0)	53 (46.1)	188 (54.3)	54 (47.4)
Female	169 (49.0)	62 (53.9)	158 (45.7)	60 (52.6)
BMI (SD)	15.64 (2.934)	15.61 (3.040)	19.47 (4.481)	19.95 (4.833)
Baseline serology and/or Positive RT-PCR results for SARS-CoV-2, n (%)*	37 (10.7)	16 (13.9)	45 (13.0)	14 (12.3)
Negative	306 (88.7)	98 (85.2)	300 (86.7)	100 (87.7)

*Results missing for 3 participants (2 to 11 years) and 1 participant (12 to 17 years), respectively.

SD – Standard Deviation

Table 2: Non-inferiority of COVOVAX™ (Pediatric) to COVOVAX™ (Adult) in terms of Anti-S IgG and neutralizing antibodies at Visit 3-Day 36 (Immunogenicity Analysis Population)

Multiple Imputation [1] Results Using Rubin's Method [2]	2 to 11 years		12-17 years	
	COVOVAX[PD] (N=326)	COVOVAX[AD] (N=340)	COVOVAX[PD] (N=333)	COVOVAX[AD] (N=340)
Anti-S IgG				
GMEU [3] with 95% CI	216369.87	142586.82	171204.19	142122.16
	(202056.83, 231696.80)	(133280.59, 152542.85)	(158598.33, 184812.00)	(131793.34, 153260.47)
GMEU Ratio [3] with 95% CI	**1.52 (1.38, 1.67)**		**1.20 (1.08, 1.34)**	
Neutralizing antibodies				
GMT [3] with 95% CI	6940.82	3602.39	4732.36	3568.04
	(6349.74, 7586.93)	(3300.10, 3932.37)	(4323.63, 5179.73)	(3264.78, 3899.48)
GMT Ratio [3] with 95% CI	**1.93 (1.70, 2.18)**		**1.33 (1.17, 1.50)**	

[1] Multiple Imputation model with classification variables vaccine, sex, and continuous covariates log baseline titer used to impute 50 values for each missing value.

[2] Rubin's method in PROC MIANALYZE used to pool estimates and SE across the 50 multiply imputed datasets.

[3] Pooled ANCOVA results, LS Mean and it's 95% CI values by treatment were used to generate the GMEU / GMT and 95% CI and the differences in LS Means and corresponding 95% CI limits were used to obtain GMEU / GMT Ratio and 95% CI using back transforming to the original scale.

PD – Pediatric cohort, AD – Adult cohort. Specified age group detail is applicable for pediatric cohort (i.e. 12 to 17 years and 2 to 11 years).

Table 3: Summary of Anti-S IgG antibodies and Neutralizing antibodies (nAb) against SARS-CoV-2 (Immunogenicity analysis population)

Timepoint	Parameters	2 to 11 years				12-17 years			
		Anti-S IgG antibodies		Neutralizing antibodies		Anti-S IgG antibodies		Neutralizing antibodies	
		SII-NVX-CoV2373 (N=326)	Placebo (N=106)	SII-NVX-CoV2373 (N=326)	Placebo (N=106)	SII-NVX-CoV2373 (N=333)	Placebo (N=108)	SII-NVX-CoV2373 (N=333)	Placebo (N=108)
Baseline Summary of Titer	n	326	106	326	106	333	108	333	107
	GMEU / GMT	1261.1	1346.0	59.7	67.1	1664.2	1366.6	54.8	51.2
	95 % CI	(1048.5, 1516.9)	(953.2, 1900.7)	(49.9, 71.3)	(47.5, 94.7)	1413.7, 1959.1	1033.1, 1807.8	47.0, 63.8	40.0, 65.5
22 days after first dose Summary of Titer	n	325	106	96	31	332	108	158	51
	GMEU / GMT	75558.3	1754.8	2451.5	95.7	72660.4	1614.6	3526.3	137.8
	95 % CI	(65471.0, 87199.9)	(1203.0, 2559.7)	(1821.0, 3300.1)	(45.0, 203.4)	63586.3, 83029.4	1174.7, 2219.3	(2857.5, 4351.7)	(78.6, 241.5)
	GMFR	60.1	1.3	43.7	1.4	43.6	1.2	60.7	2.4
	95 % CI	(52.8, 68.3)	(1.1, 1.6)	(33.0, 57.8)	(0.9, 2.1)	38.0, 50.0	1.0, 1.5	(48.5, 76.0)	(1.5, 3.6)
14 days after second dose Summary of Titer	n	325	103	325	103	330	107	329	105
	GMEU / GMT	214029.6	1626.2	6916.2	90.3	170193.6	1480.4	4686.4	58.3
	95 % CI	(201610.9, 227213.1)	(1126.0, 2348.8)	(6322.8, 7565.5)	(62.6, 130.3)	157429.7, 183992.4	1110.1, 1974.3	(4282.0, 5129.0)	(43.8, 77.5)
	GMFR	169.2	1.2	115.3	1.3	101.9	1.1	84.9	1.1
	95 % CI	139.4, 205.4	1.0, 1.4	(96.8, 137.4)	(1.1, 1.6)	85.4, 121.7	0.9, 1.3	(72.1, 100.0)	(1.0, 1.3)
180 days after first dose Summary of Titer	n	313	97	92	28	325	67	118	19
	GMEU / GMT	44882.1	4356.0	1604.6	152.3	51961.6	9311.4	2683.2	357.0
	95 % CI	(41578.6, 48448.0)	(3181.8, 5963.5)	(1341.0, 1920.0)	(69.0, 335.9)	(47560.1, 56770.5)	(6388.9, 13570.9)	(2227.8, 3231.7)	(146.2, 871.7)
	GMFR	37.2	3.4	29.0	2.4	31.0	8.1	45.3	7.2

95 % CI   (30.9, 44.7)   (2.5, 4.5)   (20.7, 40.6)   (1.4, 3.9)   (25.6, 37.4)   (5.5, 11.9)   (33.4, 61.3)   (3.4, 15.2)

n: number of participants with a non-missing value at respective visit. GMEU: Geometric Mean ELISA Units; GMT: Geometric Mean Titer, GMFR: geometric mean fold rise

Table 4: Proportion of Participants with Seroconversion for Anti-S IgG Antibodies and neutralizing antibodies (Immunogenicity analysis population)

Timepoint	Parameters	2-11 years		12-17 years	
		SII-NVX-CoV2373 (N=326)	Placebo (N=106)	SII-NVX-CoV2373 (N=333)	Placebo (N=108)
		Anti-S IgG antibodies			
22 days after first dose	N Evaluated	325	106	332	108
	n (%)	318 (97.8)	6 (5.7)	317 (95.5)	4 (3.7)
	95% CI	95.6, 99.1	2.1, 11.9	92.7, 97.4	1.0, 9.2
14 days after second dose	N Evaluated	325	103	330	107
	n (%)	322 (99.1)	8 (7.8)	326 (98.8)	3 (2.8)
	95% CI	97.3, 99.8	3.4, 14.7	96.9, 99.7	0.6, 8.0
180 days after first dose	N Evaluated	313	97	325	67
	n (%)	295 (94.2)	42 (43.3)	298 (91.7)	49 (73.1)
	95% CI	(91.1, 96.6)	(33.3, 53.7)	(88.1, 94.5)	(60.9, 83.2)
		Neutralizing antibodies			
22 days after first dose	N Evaluated	96	31	158	51
	n (%)	94 (97.9)	4 (12.9)	154 (97.5)	13 (25.5)
	95% CI	(92.7, 99.7)	(3.6, 29.8)	(93.6, 99.3)	(14.3, 39.6)
14 days after second dose	N Evaluated	325	103	329	105
	n (%)	318 (97.8)	11 (10.7)	322 (97.9)	9 (8.6)
	95% CI	(95.6, 99.1)	(5.5, 18.3)	(95.7, 99.1)	(4.0, 15.6)
180 days after first dose	N Evaluated	92	28	118	19
	n (%)	85 (92.4)	12 (42.9)	111 (94.1)	14 (73.7)
	95% CI	(84.9, 96.9)	(24.5, 62.8)	(88.2, 97.6)	(48.8, 90.9)

Table 5: Summary of Solicited AEs (Safety Population)

	2-11 years				12-17 years			
	First dose		Second dose		First dose		Second dose	
	SII-NVX-CoV2373 (N=345) n (%) [E]	Placebo (N=115) n (%) [E]	SII-NVX-CoV2373 (N=333) n (%) [E]	Placebo (N=112) n (%) [E]	SII-NVX-CoV2373 (N=346) n (%) [E]	Placebo (N=114) n (%) [E]	SII-NVX-CoV2373 (N=335) n (%) [E]	Placebo (N=110) n (%) [E]
Participants with at Least One Solicited AE	122 (35.4) [248]	15 (13.0) [29]	163 (48.9) [367]	13 (11.6) [27]	139 (40.2) [272]	26 (22.8) [54]	129 (38.5) [329]	20 (18.2) [42]
Participants with at Least One Local Solicited AE	84 (24.3) [118]	10 (8.7) [15]	87 (26.1) [136]	9 (8.0) [17]	90 (26.0) [123]	12 (10.5) [16]	86 (25.7) [140]	10 (9.1) [13]
Injection Site Pain	81 (23.5) [81]	9 (7.8) [9]	83 (24.9) [83]	9 (8.0) [9]	85 (24.6) [85]	11 (9.6) [11]	82 (24.5) [82]	9 (8.2) [9]
Injection Site Tenderness	27 (7.8) [27]	3 (2.6) [3]	20 (6.0) [20]	1 (0.9) [1]	23 (6.6) [23]	1 (0.9) [1]	29 (8.7) [29]	3 (2.7) [3]
Injection Site Swelling	6 (1.7) [6]	2 (1.7) [2]	14 (4.2) [14]	2 (1.8) [2]	8 (2.3) [8]	2 (1.8) [2]	13 (3.9) [13]	0
Injection Site Induration	2 (0.6) [2]	1 (0.9) [1]	5 (1.5) [5]	2 (1.8) [2]	7 (2.0) [7]	1 (0.9) [1]	10 (3.0) [10]	1 (0.9) [1]
Injection Site Erythema	2 (0.6) [2]	0	14 (4.2) [14]	3 (2.7) [3]	0	1 (0.9) [1]	6 (1.8) [6]	0
Participants with at Least One Systemic Solicited AE	80 (23.2) [130]	10 (8.7) [14]	133 (39.9) [231]	8 (7.1) [10]	87 (25.1) [149]	19 (16.7) [38]	99 (29.6) [189]	17 (15.5) [29]
Fever	50 (14.5) [50]	6 (5.2) [6]	99 (29.7) [99]	1 (0.9) [1]	27 (7.8) [27]	7 (6.1) [7]	58 (17.3) [58]	3 (2.7) [3]
Headache	19 (5.5) [19]	2 (1.7) [2]	37 (11.1) [37]	4 (3.6) [4]	39 (11.3) [39]	11 (9.6) [11]	42 (12.5) [42]	9 (8.2) [9]
Malaise	17 (4.9) [17]	2 (1.7) [2]	19 (5.7) [19]	1 (0.9) [1]	14 (4.0) [14]	2 (1.8) [2]	23 (6.9) [23]	2 (1.8) [2]
Fatigue	15 (4.3) [15]	1 (0.9) [1]	18 (5.4) [18]	2 (1.8) [2]	30 (8.7) [30]	5 (4.4) [5]	30 (9.0) [30]	4 (3.6) [4]
Myalgia	12 (3.5) [12]	2 (1.7) [2]	14 (4.2) [14]	1 (0.9) [1]	16 (4.6) [16]	5 (4.4) [5]	14 (4.2) [14]	4 (3.6) [4]
Arthralgia	4 (1.2) [4]	0	11 (3.3) [11]	0	15 (4.3) [15]	3 (2.6) [3]	10 (3.0) [10]	4 (3.6) [4]
Nausea	5 (1.4) [5]	0	20 (6.0) [20]	0	7 (2.0) [7]	2 (1.8) [2]	8 (2.4) [8]	2 (1.8) [2]
Vomiting	8 (2.3) [8]	1 (0.9) [1]	13 (3.9) [13]	1 (0.9) [1]	1 (0.3) [1]	3 (2.6) [3]	4 (1.2) [4]	1 (0.9) [1]

Figure 1: CONSORT Flow Chart – 12 to 17 years

```
                    ┌─────────────────┐
                    │    Screened     │
                    │    (n=470)      │
                    └────────┬────────┘
                             │           ┌──────────────────────┐
                             ├──────────►│ Screen failure (n=9) │
                             │           └──────────────────────┘
                    ┌────────▼────────┐
                    │   Randomized    │
                    │    (n=461)      │
                    └────────┬────────┘
                             │           ┌──────────────────────────┐
                             ├──────────►│ Not vaccinated* (n=1)    │
                             │           └──────────────────────────┘
            ┌────────────────┴────────────────┐
            │                                 │
  ┌─────────▼─────────┐            ┌──────────▼──────────┐
  │  SII-NVX-CoV2373  │            │     Placebo         │
  │     (n=346)       │            │     (n=114)         │
  └─────────┬─────────┘            └──────────┬──────────┘
            │                                 │
  ┌─────────▼─────────┐            ┌──────────▼──────────┐
  │  1st dose         │            │  1st dose           │
  │  (n=346)          │            │  (n=114)            │
  └─────────┬─────────┘            └──────────┬──────────┘
            │    ┌───────────────────┐        │    ┌───────────────────┐
            ├───►│ Withdrawal by     │        ├───►│ Withdrawal by     │
            │    │ participant (n=11)│        │    │ participant (n=4) │
            │    └───────────────────┘        │    └───────────────────┘
  ┌─────────▼─────────┐            ┌──────────▼──────────┐
  │  2nd dose         │            │  2nd dose           │
  │                   │            │  (n=110)            │
  └─────────┬─────────┘            └──────────┬──────────┘
            │    ┌───────────────────┐        │    ┌───────────────────┐
            ├───►│ Withdrawal by     │        ├───►│ Withdrawal by     │
            │    │ participant (n=2) │        │    │ participant (n=1) │
            │    └───────────────────┘        │    └───────────────────┘
  ┌─────────▼─────────┐            ┌──────────▼──────────┐
  │  Day 36 visit     │            │  Day 36 visit       │
  │  (n= 332)         │            │  (n=109)            │
  └─────────┬─────────┘            └──────────┬──────────┘
            │  ┌──────────────────────────┐   │  ┌──────────────────────────┐
            ├─►│ Withdrawal by participant│   ├─►│ Withdrawal by participant│
            │  │ (n=4)                    │   │  │ (n=2)                    │
            │  │ Lost to follow up (n=2)  │   │  │ Lost to follow up (n=4)  │
            │  └──────────────────────────┘   │  └──────────────────────────┘
  ┌─────────▼─────────┐            ┌──────────▼──────────┐
  │  Day 180 visit    │            │  Day 180 visit      │
  │  (n= 328)         │            │  (n=103)            │
  └─────────┬─────────┘            └──────────┬──────────┘
            │                                 │
  ┌─────────▼─────────────────┐   ┌──────────▼──────────────────┐
  │ Safety Population (n=346) │   │ Safety Population (n=114)    │
  │ IA Population (n=333)     │   │ IA Population (n=108)        │
  └───────────────────────────┘   └─────────────────────────────┘
```

*IA – Immunogenicity analysis; * Withdrawal by participant before vaccination.*

Figure 2: CONSORT Flow Chart – 2 to 11 years

IA – Immunogenicity analysis; * Withdrawal by participant before vaccination.

Supplementary tables:

Table S1: Summary of Anti-S IgG and neutralizing antibodies in baseline seronegative and RT-PCR negative (Immunogenicity Analysis Population)					
		2-11 years		12-17 years	
Timepoint	Parameters	SII-NVX-CoV2373 (N=294)	Placebo (N=93)	SII-NVX-CoV2373 (N=290)	Placebo (N=96)
Anti-S IgG antibodies					
Baseline Summary of Titer	N	294	93	290	96
	GMEU/ GMT	1024.8	1104.2	**1356.5**	**1169.8**
	95 % CI	851.7, 1233.0	768.6, 1586.4	1147.6, 1603.5	870.4, 1572.1
Day 22 (+7)	N	293	93	289	96
Summary of Titer	GMEU / GMT	70905.8	1410.1	**68598.7**	**1446.0**
	95 % CI	60710.4, 82813.4	949.7, 2093.7	59394.8, 79228.8	1020.5, 2049.0
	GMFR	69.4	1.3	**50.5**	**1.2**
	95 % CI	61.5, 78.4	1.0, 1.6	44.4, 57.5	1.0, 1.6
Day 36 (+7)	N	293	91	287	96
Summary of Titer	GMEU	213552.3	1356.1	**168185.0**	**1326.5**
	95 % CI	200427.3, 227536.8	914.8, 2010.1	154173.4, 183470.1	973.5, 1807.4
	GMFR	207.8	1.2	**123.8**	**1.1**
	95 % CI	170.6, 253.1	1.0, 1.5	102.8, 149.0	0.9, 1.4
Day 180 (+28)	N	284	86	282	59
Summary of Titer	GMEU	44323.3	4303.0	52167.6	9249.1
	95 % CI	(40865.4, 48073.8)	(3046.6, 6077.4)	(47367.6, 57454.1)	(6124.8, 13967.0)
	GMFR	44.4	4.1	38.3	9.3
	95 % CI	(36.8, 53.5)	(3.0, 5.5)	(31.4, 46.7)	(6.3, 13.9)
Neutralizing antibodies					
Baseline Summary of Titer	N	294	93	290	95
	GMT	50.3	55.9	**46.7**	**49.1**
	95 % CI	(42.0, 60.1)	(39.6, 79.1)	40.1, 54.5	37.5, 64.2
Day 22 (+7)	N	88	26	131	46
Summary of Titer	GMT	2384.8	84.4	3214.0	131.5
	95 % CI	(1733.7, 3280.4)	(37.2, 191.4)	(2517.2, 4103.8)	(71.5, 242.1)
	GMFR	50.1	1.5	66.1	2.3
	95 % CI	(38.2, 65.9)	(0.9, 2.5)	(51.5, 84.8)	(1.4, 3.6)
Day 36 (+7)	N	293	91	285	95
Summary of Titer	GMT	6996.6	75.3	**4645.4**	**56.4**
	95 % CI	(6357.0, 7700.6)	(51.4, 110.1)	4204.5, 5132.5	41.6, 76.4
	GMFR	138.4	1.3	**98.4**	**1.1**
	95 % CI	(116.3, 164.6)	(1.1, 1.6)	83.3, 116.3	1.0, 1.3
Day 180 (+28)	N	85	24	96	17
Summary of Titer	GMT	1595.3	155.4	2635.0	376.7

Timepoint	Parameters	2-11 years		12-17 years	
		SII-NVX-CoV2373 (N=294)	Placebo (N=93)	SII-NVX-CoV2373 (N=290)	Placebo (N=96)
	95 % CI	(1316.7, 1932.8)	(63.5, 380.3)	(2132.3, 3256.3)	(144.9, 979.6)
	GMFR	34.4	2.9	54.2	7.4
	95 % CI	(24.7, 47.9)	(1.8, 4.6)	(39.2, 74.9)	(3.4, 16.2)

Table S1: Summary of Anti-S IgG and neutralizing antibodies in baseline seronegative and RT-PCR negative (Immunogenicity Analysis Population)

Table S2: Proportion of Participants with Seroconversion for Anti-S IgG Antibodies and neutralizing antibodies in baseline seronegative and RT-PCR negative (Immunogenicity Analysis Population)

Timepoint	Parameters	2-11 years		12-17 years	
		SII-NVX-CoV2373 (N=294)	Placebo (N=93)	SII-NVX-CoV2373 (N=290)	Placebo (N=96)
		Anti-S IgG antibodies			
22 days after first dose	N Evaluated	293	93	289	96
	n (%)	293 (100.0)	5 (5.4)	281 (97.2)	4 (4.2)
	95% CI	(98.7, 100.0)	(1.8, 12.1)	94.6, 98.8	1.1, 10.3
14 days after second dose	N Evaluated	293	91	287	96
	n (%)	293 (100.0)	7 (7.7)	285 (99.3)	3 (3.1)
	95% CI	(98.7, 100.0)	(3.1, 15.2)	97.5, 99.9	0.6, 8.9
	N Evaluated	284	86	282	59
180 days after first dose	n (%)	273 (96.1)	41 (47.7)	268 (95.0)	45 (76.3)
	95% CI	(93.2, 98.1)	(36.8, 58.7)	(91.8, 97.3)	(63.4, 86.4)
		Neutralizing antibodies			
22 days after first dose	N Evaluated	88	26	131	46
	n (%)	88 (100.0)	4 (15.4)	127 (96.9)	11 (23.9)
	95% CI	(95.9, 100.0)	(4.4, 34.9)	(92.4, 99.2)	(12.6, 38.8)
14 days after second dose	N Evaluated	293	91	286	94
	n (%)	291 (99.3)	10 (11.0)	282 (98.6)	7 (7.4)
	95% CI	(97.6, 99.9)	(5.4, 19.3)	(96.5, 99.6)	(3.0, 14.7)
180 days after first dose	N Evaluated	85	24	96	17
	n (%)	82 (96.5)	10 (41.7)	91 (94.8)	13 (76.5)
	95% CI	(90.0, 99.3)	(22.1, 63.4)	(88.3, 98.3)	(50.1, 93.2)

Table S3: IgG geometric mean titres after two doses of vaccination for SARS-CoV-2 strains by study day for participants receiving SII-NVX-COV2373

Age Group	Parameter	IgG GMTs and GMFR					
	Strain	Delta			Omicron BA.1		
	Study Day	Baseline	Day 36	Day 180	Baseline	Day 36	Day 180
2-11 years	GMT (95% CI)	2433.7 (1424.5, 4158.0)	251510.2 (204159.5, 309843.0)	38347.0 (27424.8, 53619.1)	1080.3 (704.3, 1656.9)	105031.3 (83738.1, 131739.0)	22536.7 (17587.9, 28878.0)
	GMFR (95% CI)	-	103.3 (61.6, 173.4)	16.9 (9.5, 30.2)	-	97.2 (67.1, 140.8)	22.2 (14.9, 33.0)
12-17 years	GMT (95% CI)	2158.8 (1203.4, 3872.7)	157379.2 (122688.8, 201878.3)	55795.3 (41836.2, 74411.9)	860.2 (563.9, 1312.2)	74971.0 (57583.6, 97608.5)	32008.0 (23761.3, 43116.9)
	GMFR (95% CI)	-	72.9 (41.9, 127.0)	25.8 (13.4, 49.9)	-	87.2 (57.3, 132.6)	37.2 (21.7, 63.7)

Age Group	Parameter	IgG GMTs and GMFR		
	Strain	Omicron BA.5		
	Study Day	Baseline	Day 36	Day 180
2-11 years	GMT (95% CI)	1055.3 (677.8, 1642.9)	97840.4 (80494.6, 118923.9)	23087.7 (17941.7, 29709.7)
	GMFR (95% CI)		92.7 (62.2, 138.1)	23.2 (14.5, 37.1)
12-17 years	GMT (95% CI)	793.3 (506.7, 1242.0)	71869.4 (56343.4, 91673.9)	32456.0 (23936.3, 44008.0)
	GMFR (95% CI)		90.6 (59.2, 138.6)	40.9 (22.7, 73.9)

Table S4: hACE2 receptor binding inhibition geometric mean titres after two doses of vaccination for Wuhan and variant SARS-CoV-2 strains by study day for participants receiving SII-NVX-COV2373

Age Group	Parameter	hACE2 Inhibition titre of antibodies					
	Strain	Wuhan			Delta		
	Study Day	Baseline	Day 36	Day 180	Baseline	Day 36	Day 180
2-11 years	GMT (95% CI)	10.5 (7.8, 14.2)	704.6 (581.5, 853.9)	129.9 (95.8, 176.0)	12.6 (9.1, 17.6)	538.9 (437.3, 664.2)	131.7 (99.0, 175.2)
	GMFR (95% CI)	-	67.0 (49.3, 91.1)	13.2 (9.1, 19.0)	-	42.7 (31.2, 58.5)	11.1 (7.6, 16.1)
12-17 years	GMT (95% CI)	9.5 (7.1, 12.7)	464.5 (363.8, 593.1)	169.4 (130.4, 220.1)	11.6 (8.6, 15.7)	337.0 (262.7, 432.3)	211.7 (161.8, 276.9)
	GMFR (95% CI)	-	48.9 (33.9, 70.6)	17.8 (12.2, 26.1)	-	29.0 (20.3, 41.5)	18.2 (12.6, 26.3)

Age Group	Parameter	hACE2 Inhibition titre of antibodies					
	Strain	Omicron BA.1			Omicron BA.5		
	Study Day	Baseline	Day 36	Day 180	Baseline	Day 36	Day 180
2-11 years	GMT (95% CI)	6.6 (5.4, 8.2)	173.7 (122.0, 247.2)	57.3 (41.8, 78.5)	7.9 (6.1, 10.2)	229.4 (163.7, 321.5)	91.9 (68.6, 123.0)
	GMFR (95% CI)	-	26.2 (18.3, 37.6)	9.0 (6.4, 12.6)	-	29.1 (21.1, 40.3)	12.1 (8.6, 17.0)
12-17 years	GMT (95% CI)	6.0 (5.0, 7.2)	122.4 (86.9, 172.4)	77.1 (56.3, 105.6)	6.5 (5.3, 8.0)	158.1 (108.9, 229.6)	137.6 (101.0, 187.5)
	GMFR (95% CI)	-	20.4 (14.2, 29.4)	12.8 (9.0, 18.4)	-	24.2 (16.6, 35.5)	21.1 (14.4, 30.8)